BioCancell Therapeutics announces auction of common stock

Download PDF Copy

Nov 18 2010

BioCancell Therapeutics Inc. (TASE: BICL) today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.

The auction will commence at 3:15 p.m. Israel time on Thursday, November 18, 2010, and will close at 5:00 p.m. on the same day. To participate in the auction, investors must submit their bids to authorized entities, as more fully described in the prospectus.

Source:

BioCancell Therapeutics Inc.

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

Experts chart path to bring microbiome science into routine clinical care

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Traditional Chinese medicine targets cholesterol metabolism for cancer treatment

How microRNA is transforming science: From discovery to diagnostics

Redefining control and consistency in anaerobic microbiome workflows

Scientists use AI to build mutation-proof antibodies for SARS-CoV-2

Scaling B-cell cloning workflows for antibody development

New antiviral compounds show broad protection against COVID-19 variants

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.